Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.
Stocks · News reference
Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19